Search Bar & Filters
Found 105 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the long-term safety and effects of vedolizumab given as a subcutaneous injection in children and teenagers aged 2 to 17 years who have moderate to severe active ulcerative colitis or Crohns disease. The study aims to understand any medical problems related to the treatment, the time until hospital visits due to bowel inflammation are needed, and the impact on quality of life. This is a phase 3b extension study involving participants from a previous trial who responded well or did not respond to vedolizumab treatment. Participants who responded well in the previous study will continue to receive vedolizumab subcutaneously either via a prefilled syringe with an autoinjector pen or with a needle safety device. Dosage depends on weight, with injections given every two or four weeks for up to 120 weeks or until the treatment becomes commercially available or the study ends. Those who did not respond well or recently used corticosteroids will not receive the drug but will be followed for approximately two years as an observational group. Throughout the study, participants will visit their clinic multiple times for safety monitoring and assessments. Researchers will track adverse events and serious side effects up to 18 weeks after the last dose, as well as other safety events in the observational group. They will also measure the time to major inflammatory bowel disease events and changes in quality of life using questionnaires. The total participation time can be up to two years from the first dose.
Actively Recruiting
Researchers are studying the use of unlicensed cryopreserved cord blood units CBUs for transplantation in both children and adults with blood cancers and other related disorders. This observational study involves patients with hematologic malignancies and various inherited and acquired disorders affecting the blood and immune system. The main goal is to monitor how well neutrophil recovery occurs after transplantation using these unlicensed CBUs in multiple institutions. Participants receive unlicensed cryopreserved CBUs as part of their transplant treatment. The study includes patients of any age receiving these CBUs for approved indications. The protocol focuses on the access and distribution of these unlicensed units rather than a specific treatment intervention. The study gathers data from recipients who receive these CBUs, tracking outcomes after transplantation. Participants are monitored for neutrophil recovery at 60 and 100 days after transplant, defined by a neutrophil count of at least 500mm3. Researchers also collect information on infection transmission, infusion reactions, survival rates at one year, and incidence of acute and chronic graft versus host disease. Platelet recovery is also evaluated. Safety and efficacy outcomes are followed over time to better understand the effects of unlicensed CBUs in this patient population.
Actively Recruiting
Researchers are evaluating AZD0120, a dual-targeted CAR-T cell therapy against BCMA and CD19, compared with standard treatment regimens in people with relapsed refractory multiple myeloma RRMM. This Phase III open-label, randomized global trial aims to compare the effectiveness and safety of AZD0120 against four standard regimens DKd daratumumab, carfilzomib, dexamethasone, DPd daratumumab, pomalidomide, dexamethasone, PVd pomalidomide, bortezomib, dexamethasone, and Kd carfilzomib, dexamethasone. Participants will be randomly assigned to receive either AZD0120 or one of the four standard regimens chosen by their investigator. AZD0120 is a biological CAR-T cell therapy, while the standard regimens involve combinations of drugs administered according to routine care. The study evaluates treatment effectiveness over several years, including progression-free survival and minimal residual disease negativity. During the trial, participants will undergo regular assessments including laboratory tests and clinical evaluations to monitor disease status and treatment response. Key outcomes include progression-free survival and minimal residual disease negativity rates. Safety and effectiveness will be monitored over multiple years. The total study duration extends up to 5 years, with participants followed for outcomes such as overall survival and response rates.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug ozanimod RPC1063 in treating pediatric participants aged 2 to 17 years who have moderate to severe active ulcerative colitis UC. These participants have not responded adequately to standard treatments. The study is a combined Phase 23, randomized, double-blind trial aimed at achieving and maintaining clinical remission in this population. Participants will receive oral ozanimod at different dose levels as part of the study. The treatment involves specified doses given on specific days. The study includes two experimental groups receiving either a high or low dose of ozanimod. The trial will assess outcomes over various time points, including up to 70 weeks for pharmacokinetics and safety monitoring, and follow-up for adverse events up to 6 years. During the study, participants will be closely monitored through clinical assessments, endoscopic evaluations, and laboratory tests. Researchers will measure remission rates, clinical responses, symptomatic remission, corticosteroid-free remission, endoscopic improvement, and lymphocyte counts. Safety will be tracked by documenting adverse events and serious adverse events throughout the study and follow-up period. The primary outcome is the proportion of participants achieving clinical remission at Week 52.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating remternetug, an investigational drug, to study its effects on asymptomatic individuals at risk for dominantly inherited Alzheimers disease DIAD caused by genetic mutations. The study aims to assess whether remternetug can prevent or reduce amyloid beta accumulation, a protein linked to Alzheimers progression, and to evaluate its impact on various disease biomarkers and safety. This research involves two stages Stage 1 focuses on amyloid beta changes, while Stage 2 examines downstream biomarkers related to disease progression compared to control groups. Participants will receive remternetug or a matching placebo as a subcutaneous injection every 12 weeks in a randomized, double-blind design. Following Stage 1, an open-label phase will begin after the last dose, allowing participants to receive remternetug openly. The study uses brain imaging, blood, and spinal fluid tests to monitor biomarker changes and treatment effects over time, with assessments scheduled up to 192 weeks. Participants are involved in regular visits for cognitive and clinical evaluations, brain scans using PET imaging, and collection of fluid samples to track biomarker changes. Researchers will closely monitor safety, tolerability, and cognitive measures throughout the study. The total participation duration extends over multiple years, with ongoing assessments to understand the drugs effect on disease progression and participant well-being.
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are evaluating combination chemotherapy treatments for patients with newly diagnosed diffuse anaplastic Wilms tumors DAWT and relapsed favorable histology Wilms tumors FHWT. This phase II trial aims to compare different chemotherapy regimens to see if adding drugs like vincristine and irinotecan improves survival outcomes for these patients, based on historical data. The study also explores kidney toxicity, genetic factors, and surgical outcomes related to these tumors. Patients are assigned to one of two treatment groups. Arm I Regimen UH-3 involves multiple cycles of vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan administered intravenously every 21 days with radiation therapy as needed. Arm II Regimen ICECycloTopo includes cycles of carboplatin, etoposide, ifosfamide, cyclophosphamide, and topotecan given intravenously every 21 days with surgery andor radiation as clinically indicated. Both groups undergo various imaging scans and biopsies throughout treatment. Participants are closely monitored with CT, PET, X-rays, MRI, ultrasound, bone scans, blood tests, and biopsies during the trial. After treatment, follow-up visits occur every 3 months for the first two years, then every 6 months for years 3 and 4, and once at year 5. The primary outcomes measured are event-free survival and overall survival up to five years. The study also collects blood, urine, and tumor tissue samples for future research and monitors treatment side effects and kidney function.
Actively Recruiting
Researchers are evaluating the use of nipocalimab in pregnant individuals at risk for severe Hemolytic Disease of the Fetus and Newborn HDFN. The study aims to compare nipocalimab with a placebo to see if it can reduce the risk of fetal anemia, a condition where the babys red blood cell levels drop too low during pregnancy. This phase 3, randomized, placebo-controlled, and triple-blind study is conducted across multiple centers. Participants will receive either nipocalimab or a matching placebo through weekly intravenous infusions starting from randomization until 35 weeks of gestational age. The study groups include an experimental group receiving nipocalimab and a placebo group receiving an inactive treatment, both administered once weekly. The study timeline spans from randomization during weeks 13 to 18 of pregnancy through delivery and includes follow-up through the neonatal period and beyond. Participants will undergo various assessments including lab tests, fetal DNA testing, and monitoring of maternal and neonatal health outcomes. Researchers will measure the percentage of pregnancies without fetal loss, intrauterine transfusions, hydrops fetalis, or neonatal death, among many other maternal and infant health parameters. Follow-up extends to 104 weeks for some infant assessments, including growth and development, while maternal safety and pregnancy complications are also monitored up to 24 weeks postpartum. This comprehensive monitoring aims to capture the effect of nipocalimab on both mother and baby throughout pregnancy and after birth.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia FNAIT, a condition affecting unborn and newborn babies. This Phase 3 randomized study compares nipocalimab with intravenous immunoglobulin IVIG treatment in pregnant women at risk of FNAIT. The trial is led by Janssen Research & Development, LLC and focuses on improving outcomes for fetuses and neonates facing serious bleeding risks. Pregnant participants with specific antibodies against HPA-1a andor HPA-5b are randomly assigned to receive either nipocalimab or IVIG. Nipocalimab is given intravenously starting between weeks 13 and 18 of pregnancy until delivery. IVIG is also given intravenously, starting at week 12 for high-risk pregnancies or week 20 for standard-risk pregnancies, along with oral prednisone which is tapered off after delivery based on the doctors judgment or participant tolerance. During the study, participants undergo regular assessments including blood tests to monitor platelet counts in their newborns, evaluation of bleeding events, and tracking of any adverse effects in both the mother and child. The main outcome is the presence of death, severe bleeding, or very low platelet counts in the fetus or newborn up to one week after birth. Longer-term follow-up includes developmental assessments of the infant at one and two years. The total study duration extends up to the end of 2029 with safety monitoring through the first 24 weeks postpartum and infant follow-up for up to 104 weeks.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating investigational study drugs for people with a genetic mutation that causes Alzheimers disease AD. The study focuses on those who either carry this mutation or are at risk but unaware of their genetic status. It aims to assess whether these drugs can prevent or slow the buildup of amyloid beta Ab2 plaques in the brain and later evaluate the impact on other Alzheimers disease biomarkers and disease progression. Participants will receive subcutaneous injections of remternetug or a matching placebo every 12 weeks during Stage 1, which is a blinded, placebo-controlled period lasting up to 4 years. After this, Stage 2 is an open-label period of 4 years where all mutation carriers will receive the active drug. Those initially on placebo will follow the same dose escalation as Stage 1, while those on active drug will continue their established dose. The design includes randomization and blinding for treatment and mutation status, with a shared placebo group across study arms. During the study, participants will undergo regular clinical and cognitive assessments, magnetic resonance imaging MRI, amyloid PET imaging, and cerebrospinal fluid CSF analysis. Researchers will monitor amyloid beta accumulation, downstream biomarkers like tau proteins and neurofilament light, and subtle cognitive changes. Safety, tolerability, and adherence will also be tracked. The total participation can last up to 8 years, including both treatment stages and follow-up assessments.
1-10 of 105
1